Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s stock price fell 1.8% on Friday . The company traded as low as $677.99 and last traded at $668.25. 110,467 shares changed hands during trading, a decline of 82% from the average session volume of 621,862 shares. The stock had previously closed at $680.61.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on REGN. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Bank of America restated an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.
Read Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Down 1.1 %
The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $73.36 billion, a price-to-earnings ratio of 17.51, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The firm's 50-day simple moving average is $694.15 and its 200-day simple moving average is $827.65.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the business earned $11.86 EPS. The firm's revenue was up 10.3% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.
Institutional Trading of Regeneron Pharmaceuticals
Several institutional investors have recently made changes to their positions in REGN. GSA Capital Partners LLP acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $665,000. Empowered Funds LLC boosted its position in Regeneron Pharmaceuticals by 7.1% in the third quarter. Empowered Funds LLC now owns 1,652 shares of the biopharmaceutical company's stock valued at $1,737,000 after buying an additional 109 shares in the last quarter. Atlanta Consulting Group Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $534,000. Claro Advisors LLC boosted its position in Regeneron Pharmaceuticals by 110.6% in the third quarter. Claro Advisors LLC now owns 478 shares of the biopharmaceutical company's stock valued at $502,000 after buying an additional 251 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in Regeneron Pharmaceuticals by 16.7% in the third quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company's stock valued at $9,587,000 after buying an additional 1,306 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
